All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders

Janet D. Rowley, Shalini Reshmi, Olatoyosi Sobulo, Tarannum Musvee, John Anastasi, Susana Raimondi, Nancy R. Schneider, Julio Barredo, Eduardo S. Cantu, Brigitte Schlegelberger, Frederick Behm, Norman A. Doggett, Julian Borrow, Nancy Zeleznik-Le

Research output: Contribution to journalArticle

199 Citations (Scopus)

Abstract

The involvement of 11q23-balanced translocations in acute leukemia after treatment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with increasing frequency. We and others have shown that the gene at 11q23 that is involved in all of these treatment related leukemias is MLL (also called ALL1, Htrx, and HRX). In general, the translocations in these leukemias are the same as those occurring in de novo leukemia [eg, t(9; 11), t(11; 19), and t(4; 11)], with the treatment-related leukemias accounting for no more than 5% to 10% of any particular translocation type. We have cloned the t(11; 16)(q23; p13.3) and have shown that it involves MLL and CBP(CREB binding protein). The CBP gene was recently identified as a partner gene in the t(8; 16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in treatment-related acute myeloid leukemia. We have studied eight t(11; 16) patients, all of whom had prior therapy with drugs targetting topo II with fluorescence in situ hybridization (FISH) using a probe for MLL and a cosmid contig covering the CBPgene. Both probes were split in all eight patients and the two derivative (der) chromosomes were each labeled with both probes. Use of an approximately 100-kb PAC located at the breakpoint of chromosome 16 from one patient revealed some variability in the breakpoint because it was on the der(16) in three patients, on the der(11) in another, and split in four others. We assume that the critical fusion gene is 5'MLL/3'CBP. Our series of patients is unusual because three of them presented with a myelodysplastic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dyserythropoiesis; MDS is rarely seen in 11q23 translocations either de novo or with t-AML. Using FISH and these same probes to analyze the lineage of bone marrow cells from one patient with CMMoL, we showed that all the mature monocytes contained the fusion genes as did some of the granulocytes and erythroblasts; none of the lymphocytes contained the fusion gene. The function of MLL is not well understood, but many domains could target the MLL protein to particular chrometin complexes. CBP is an adapter protein that is involved in regulating transcription. It is also involved in histone acetylation, which is thought to contribute to an increased level of gene expression. The fusion gene could alter the CBP protein such that it is constitutively active; alternatively, it could modify the chromatin- association functions of MLL.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalBlood
Volume90
Issue number2
StatePublished - Jul 15 1997
Externally publishedYes

Fingerprint

CREB-Binding Protein
Genes
Gene Fusion
Leukemia
Leukemia, Myelomonocytic, Chronic
Fusion reactions
Type II DNA Topoisomerase
Myelodysplastic Syndromes
Fluorescence In Situ Hybridization
Derivatives
Therapeutics
Leukemia, Myelomonocytic, Acute
Chromosomes, Human, Pair 16
Fluorescence
Chromosome Breakpoints
Erythroblasts
Cosmids
Proteins
Acetylation
Drug Delivery Systems

ASJC Scopus subject areas

  • Hematology

Cite this

Rowley, J. D., Reshmi, S., Sobulo, O., Musvee, T., Anastasi, J., Raimondi, S., ... Zeleznik-Le, N. (1997). All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders. Blood, 90(2), 535-541.

All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders. / Rowley, Janet D.; Reshmi, Shalini; Sobulo, Olatoyosi; Musvee, Tarannum; Anastasi, John; Raimondi, Susana; Schneider, Nancy R.; Barredo, Julio; Cantu, Eduardo S.; Schlegelberger, Brigitte; Behm, Frederick; Doggett, Norman A.; Borrow, Julian; Zeleznik-Le, Nancy.

In: Blood, Vol. 90, No. 2, 15.07.1997, p. 535-541.

Research output: Contribution to journalArticle

Rowley, JD, Reshmi, S, Sobulo, O, Musvee, T, Anastasi, J, Raimondi, S, Schneider, NR, Barredo, J, Cantu, ES, Schlegelberger, B, Behm, F, Doggett, NA, Borrow, J & Zeleznik-Le, N 1997, 'All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders', Blood, vol. 90, no. 2, pp. 535-541.
Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S et al. All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders. Blood. 1997 Jul 15;90(2):535-541.
Rowley, Janet D. ; Reshmi, Shalini ; Sobulo, Olatoyosi ; Musvee, Tarannum ; Anastasi, John ; Raimondi, Susana ; Schneider, Nancy R. ; Barredo, Julio ; Cantu, Eduardo S. ; Schlegelberger, Brigitte ; Behm, Frederick ; Doggett, Norman A. ; Borrow, Julian ; Zeleznik-Le, Nancy. / All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders. In: Blood. 1997 ; Vol. 90, No. 2. pp. 535-541.
@article{6344a8dbd1704798973dea6dcc6d5465,
title = "All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders",
abstract = "The involvement of 11q23-balanced translocations in acute leukemia after treatment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with increasing frequency. We and others have shown that the gene at 11q23 that is involved in all of these treatment related leukemias is MLL (also called ALL1, Htrx, and HRX). In general, the translocations in these leukemias are the same as those occurring in de novo leukemia [eg, t(9; 11), t(11; 19), and t(4; 11)], with the treatment-related leukemias accounting for no more than 5{\%} to 10{\%} of any particular translocation type. We have cloned the t(11; 16)(q23; p13.3) and have shown that it involves MLL and CBP(CREB binding protein). The CBP gene was recently identified as a partner gene in the t(8; 16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in treatment-related acute myeloid leukemia. We have studied eight t(11; 16) patients, all of whom had prior therapy with drugs targetting topo II with fluorescence in situ hybridization (FISH) using a probe for MLL and a cosmid contig covering the CBPgene. Both probes were split in all eight patients and the two derivative (der) chromosomes were each labeled with both probes. Use of an approximately 100-kb PAC located at the breakpoint of chromosome 16 from one patient revealed some variability in the breakpoint because it was on the der(16) in three patients, on the der(11) in another, and split in four others. We assume that the critical fusion gene is 5'MLL/3'CBP. Our series of patients is unusual because three of them presented with a myelodysplastic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dyserythropoiesis; MDS is rarely seen in 11q23 translocations either de novo or with t-AML. Using FISH and these same probes to analyze the lineage of bone marrow cells from one patient with CMMoL, we showed that all the mature monocytes contained the fusion genes as did some of the granulocytes and erythroblasts; none of the lymphocytes contained the fusion gene. The function of MLL is not well understood, but many domains could target the MLL protein to particular chrometin complexes. CBP is an adapter protein that is involved in regulating transcription. It is also involved in histone acetylation, which is thought to contribute to an increased level of gene expression. The fusion gene could alter the CBP protein such that it is constitutively active; alternatively, it could modify the chromatin- association functions of MLL.",
author = "Rowley, {Janet D.} and Shalini Reshmi and Olatoyosi Sobulo and Tarannum Musvee and John Anastasi and Susana Raimondi and Schneider, {Nancy R.} and Julio Barredo and Cantu, {Eduardo S.} and Brigitte Schlegelberger and Frederick Behm and Doggett, {Norman A.} and Julian Borrow and Nancy Zeleznik-Le",
year = "1997",
month = "7",
day = "15",
language = "English",
volume = "90",
pages = "535--541",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - All patients with the t(11; 16)(q23; p13.3) That involves MLL and CBP have treatment-related hematologic disorders

AU - Rowley, Janet D.

AU - Reshmi, Shalini

AU - Sobulo, Olatoyosi

AU - Musvee, Tarannum

AU - Anastasi, John

AU - Raimondi, Susana

AU - Schneider, Nancy R.

AU - Barredo, Julio

AU - Cantu, Eduardo S.

AU - Schlegelberger, Brigitte

AU - Behm, Frederick

AU - Doggett, Norman A.

AU - Borrow, Julian

AU - Zeleznik-Le, Nancy

PY - 1997/7/15

Y1 - 1997/7/15

N2 - The involvement of 11q23-balanced translocations in acute leukemia after treatment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with increasing frequency. We and others have shown that the gene at 11q23 that is involved in all of these treatment related leukemias is MLL (also called ALL1, Htrx, and HRX). In general, the translocations in these leukemias are the same as those occurring in de novo leukemia [eg, t(9; 11), t(11; 19), and t(4; 11)], with the treatment-related leukemias accounting for no more than 5% to 10% of any particular translocation type. We have cloned the t(11; 16)(q23; p13.3) and have shown that it involves MLL and CBP(CREB binding protein). The CBP gene was recently identified as a partner gene in the t(8; 16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in treatment-related acute myeloid leukemia. We have studied eight t(11; 16) patients, all of whom had prior therapy with drugs targetting topo II with fluorescence in situ hybridization (FISH) using a probe for MLL and a cosmid contig covering the CBPgene. Both probes were split in all eight patients and the two derivative (der) chromosomes were each labeled with both probes. Use of an approximately 100-kb PAC located at the breakpoint of chromosome 16 from one patient revealed some variability in the breakpoint because it was on the der(16) in three patients, on the der(11) in another, and split in four others. We assume that the critical fusion gene is 5'MLL/3'CBP. Our series of patients is unusual because three of them presented with a myelodysplastic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dyserythropoiesis; MDS is rarely seen in 11q23 translocations either de novo or with t-AML. Using FISH and these same probes to analyze the lineage of bone marrow cells from one patient with CMMoL, we showed that all the mature monocytes contained the fusion genes as did some of the granulocytes and erythroblasts; none of the lymphocytes contained the fusion gene. The function of MLL is not well understood, but many domains could target the MLL protein to particular chrometin complexes. CBP is an adapter protein that is involved in regulating transcription. It is also involved in histone acetylation, which is thought to contribute to an increased level of gene expression. The fusion gene could alter the CBP protein such that it is constitutively active; alternatively, it could modify the chromatin- association functions of MLL.

AB - The involvement of 11q23-balanced translocations in acute leukemia after treatment with drugs that inhibit the function of DNA topoisomerase II (topo II) is being recognized with increasing frequency. We and others have shown that the gene at 11q23 that is involved in all of these treatment related leukemias is MLL (also called ALL1, Htrx, and HRX). In general, the translocations in these leukemias are the same as those occurring in de novo leukemia [eg, t(9; 11), t(11; 19), and t(4; 11)], with the treatment-related leukemias accounting for no more than 5% to 10% of any particular translocation type. We have cloned the t(11; 16)(q23; p13.3) and have shown that it involves MLL and CBP(CREB binding protein). The CBP gene was recently identified as a partner gene in the t(8; 16) that occurs in acute myelomonocytic leukemia (AML-M4) de novo and rarely in treatment-related acute myeloid leukemia. We have studied eight t(11; 16) patients, all of whom had prior therapy with drugs targetting topo II with fluorescence in situ hybridization (FISH) using a probe for MLL and a cosmid contig covering the CBPgene. Both probes were split in all eight patients and the two derivative (der) chromosomes were each labeled with both probes. Use of an approximately 100-kb PAC located at the breakpoint of chromosome 16 from one patient revealed some variability in the breakpoint because it was on the der(16) in three patients, on the der(11) in another, and split in four others. We assume that the critical fusion gene is 5'MLL/3'CBP. Our series of patients is unusual because three of them presented with a myelodysplastic syndrome (MDS) most similar to chronic myelomonocytic leukemia (CMMoL) and one other had dyserythropoiesis; MDS is rarely seen in 11q23 translocations either de novo or with t-AML. Using FISH and these same probes to analyze the lineage of bone marrow cells from one patient with CMMoL, we showed that all the mature monocytes contained the fusion genes as did some of the granulocytes and erythroblasts; none of the lymphocytes contained the fusion gene. The function of MLL is not well understood, but many domains could target the MLL protein to particular chrometin complexes. CBP is an adapter protein that is involved in regulating transcription. It is also involved in histone acetylation, which is thought to contribute to an increased level of gene expression. The fusion gene could alter the CBP protein such that it is constitutively active; alternatively, it could modify the chromatin- association functions of MLL.

UR - http://www.scopus.com/inward/record.url?scp=0030792867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030792867&partnerID=8YFLogxK

M3 - Article

C2 - 9226152

AN - SCOPUS:0030792867

VL - 90

SP - 535

EP - 541

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -